VT News
  • Home
  • Lopsided
  • Local News
  • Timelines

24Serious

Sat, Jun 28, 2025
11:02 AM
Daily Index

Negative

24Serious

Neutral

Optimistic

Positive

Negative

24Serious

Neutral

Optimistic

Positive

Negative

24Serious

Neutral

Optimistic

Positive

Coverage Details
Total News Sources
2
Left
1
Center
0
Right
1
Unrated
0
Last Updated
45 days ago
Bias Distribution
50% Right
45 days ago
Updated 45 days ago
FDA Warns Against Unapproved Compounded GLP-1 Weight Loss Drugs Amid Safety Reports
FDA Warns Against Unapproved Compounded GLP-1 Weight Loss Drugs Amid Safety Reports

FDA Warns Against Unapproved Compounded GLP-1 Weight Loss Drugs Amid Safety Reports

News summary

Recent studies highlight the effectiveness and additional benefits of GLP-1 receptor agonist drugs for weight loss and related behaviors. A study published in the New England Journal of Medicine found that tirzepatide (marketed as Zepbound) led to significantly greater weight loss—about 20% of body weight over 72 weeks—compared to semaglutide (Ozempic/Wegovy), which resulted in about 14% weight loss. Another study reported that combining semaglutide with personalized, app-based support allowed patients to achieve similar weight loss at roughly half the usual drug dose, potentially reducing side effects and costs. Meanwhile, research from the European Congress on Obesity demonstrated that patients using GLP-1 drugs such as semaglutide or liraglutide reduced their alcohol intake by nearly two-thirds within four months, likely due to these drugs' effects on brain regions controlling cravings. However, the FDA has issued warnings against unapproved compounded versions of GLP-1 drugs due to safety risks, dosing errors, and serious adverse events. These findings underscore both the promise and the need for caution in the expanding use of GLP-1 medications for obesity and related conditions.

Story Coverage
alt
U.S. News & World Report
Left
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
46 days ago
Read Full Article
alt
Newsmax
Right
Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
45 days ago
Read Full Article
alt
U.S. News & World Report
Left
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
46 days ago
Read Full Article
alt
Newsmax
Right
Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
45 days ago
Read Full Article
Bias Distribution
50% Right
Information Sources
bd7f581c-6294-4fb3-adfe-81db52a08452538ad27c-7e41-4215-a5e1-3c6c21cfd9ff
Left 50%
Right 50%
Coverage Details
Total News Sources
2
Left
1
Center
0
Right
1
Unrated
0
Last Updated
45 days ago
Bias Distribution
50% Right
Related News
Daily Index

Negative

24Serious

Neutral

Optimistic

Positive

Negative

24Serious

Neutral

Optimistic

Positive

Negative

24Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage
alt
U.S. News & World Report
Left
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
46 days ago
Read Full Article
alt
Newsmax
Right
Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
45 days ago
Read Full Article
alt
U.S. News & World Report
Left
GLP-1 Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
46 days ago
Read Full Article
alt
Newsmax
Right
Weight Loss Drugs Cut Alcohol Cravings By Two-Thirds
45 days ago
Read Full Article
Ask VT AI
Bias Distribution
50% Right
Information Sources
bd7f581c-6294-4fb3-adfe-81db52a08452538ad27c-7e41-4215-a5e1-3c6c21cfd9ff
Left 50%
Right 50%

Related Topics

  • Nutrition
Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related Topics

  • Nutrition
Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News
  • Home
  • My feed
  • Lopsided

Top Topics

Trending in U.S.

World

Sport

VT News
VT News

VTNews.ai © 2025
All Rights Reserved

Cookie Policy
We use cookies to personalize content and ads, to provide social media features, and to analyze our traffic. We also share information about your use of our site with our social media, advertising, and analytics partners.
By continuing to use our site, you consent to our cookies. You can manage your preferences or withdraw your consent at any time by clicking on the buttons below.